The rising tide of metabolic disease has triggered a concurrent epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Despite this growing clinical burden, critical gaps remain in clinical awareness regarding disease prevalence, long-term consequences, effective risk assessment, and evidence-based management. With multiple novel therapeutic agents rapidly advancing through clinical trials for MASH, it is essential for clinicians to stay updated on these emerging treatment paradigms. Join us in this live exchange with the experts in the field to: Interpret emerging clinical data regarding new and developmental therapies for MASH. Develop individualized treatment strategies tailored to a patient's specific degree of liver fibrosis, steatosis, and concurrent metabolic comorbidities.

• CE: 1.25 CME Hours
• Supported by: Inventiva
• Organized by: Medscape Education
• For more information and to register, visit: https://events.medscapelive.org/website/97867/

We're tackling a rapidly evolving landscape of MASH. With new therapies now available for non-cirrhotic MASH with significant fibrosis, accurate patient stratification is essential. Noninvasive testing (NIT) has proven to be a highly accurate and practical tool for detecting significant liver fibrosis. This engaging session highlights the urgent unmet needs in MASH management and reviews the latest clinical data on breakthrough treatments. The live exchange between experts will dive into the practical, clinical utility of NITs for accurately assessing liver fibrosis.

• CE: 1.5 CME Hours
• Supported by: Siemens Healthineers
• Organized by: Medscape Education
• For more information and to register, visit: http://www.medscape.org/sympo/nits-in-mash

MASH, the progressive, inflammatory form of MASLD, is an increasing cause of end-stage liver disease.  The therapeutic landscape has transformed with FDA approvals of resmetirom and semaglutide; optimal agent selection is complex.  FGF21 analogs are in clinical development. This program is designed for those who manage patients with MASH. 

• CE: 1.5 CME Hours
• Supported by: Novo Nordisk
• Organized by: Voxmedia LLC
• For more information and to register, visit: https://symposiareg.com/22614/

As emerging therapies expand the potential for functional cure in chronic hepatitis B, this endpoint may be appropriate for some patients, but not all. This symposium will explore individualized treatment goals, including durable viral suppression, partial cure, and functional cure, and how patient characteristics and preferences guide treatment decisions.

• CE: 1.5 CME Hours
• Supported by: Aligos Therapeutics
• Organized by: Clinical Care Options, LLC dba Decera Clinical Education
• For more information and to register, visit: http://deceraclinical.com/education/2026HBVCareDenver

With a functional hep B cure on the horizon, providers must prepare for changing therapeutic guidelines. Join Hepatitis B Foundation Experts Drs. Su Wang, Mark Sulkowski, and Yasmin Ibrahim in person or via livestream on Nov 7th for an interactive symposium on the latest hep B treatment updates.

• CE: 1.25 CME Hours
• Supported by: GSK
• Organized by: PRIME Education, LLC
• For more information and to register, visit: https://primeinc.org/live/paving-way-functional-cure-integrating-therapeutic-advances-latest-guidelines

Join leading AATD experts while attending The Liver Meeting® 2026! This activity will equip clinicians with tools to improve care for patients with AATD-associated liver disease. Learn about diagnosis and the clinical profiles of emerging therapies. Gain insight on coordinating care then join the live Q&A!

• CE: 1.0 CME Hours
• Supported by: Takeda
• Organized by: Answers in CME
• For more information and to register, visit: https://www.answersincme.com/021445

 Primary sclerosing cholangitis (PSC) is a rare, progressive chronic liver disease, often associated with inflammatory bowel disease, that can lead to severe liver damage, cirrhosis, and liver failure if left untreated. This engaging, newsroom-style live symposium will feature expert faculty who will discuss the latest clinical evidence and best practices for diagnosing and managing PSC and its related complications. This dynamic event will feature a professional host, a patient testimonial, and plenty of time to interact with and ask questions of the faculty, who are leaders in the field. Attendees will come away with an in-depth understanding of PSC diagnosis and management, including the latest information on emerging therapies in clinical trials. So, join us for Breaking News in PSC and learn from the best!

• CE: 1.25 CME Hours
• Supported by: Mirum Pharmaceuticals
• Organized by: Medscape Education
• For more information and to register, visit: https://events.medscapelive.org/website/98217/

This symposium offers expert perspectives and practical insights for navigating complex PBC pruritus cases and optimizing individualized patient care. Faculty will review challenging, real-world cases and examine nuanced clinical decision-making beyond first-line management, including differential diagnosis, available treatment options, and the interconnected burden of itch, fatigue, and quality of life. 
 

• CE: 1.25 CME Hours
• Supported by: Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A.
• Organized by: Chronic Liver Disease Foundation (CLDF)
• CME Provided by: Jointly provided by the University of Cincinnati and the Chronic Liver Disease Foundation.This activity is supported through an educational grant by Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A.

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) are rare, heritable cholestatic liver diseases. Typically recognized in pediatric settings, they can present across the lifespan and pose particular challenges in adults. This interactive, case-based symposium will improve clinicians' competence in recognizing, diagnosing, and managing PFIC and ALGS in adults.

• Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
• Pharmacists: 1.50 contact hours (0.15 CEUs)
• Nurse Practitioners/Nurses: 1.50 Nursing contact hours
• Supported by: Ipsen Biopharmaceuticals, Inc.
• Organized by: Clinical Care Options, LLC dba Decera Clinical Education in partnership with Progressive Familial Intrahepatic Cholestasis (PFIC) Network
• For more information and to register, visit: https://deceraclinical.com/CholestasisDenver26

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) frequently present diagnostic challenges in adult clinical practice due to variable phenotypes, delayed recognition, and overlapping hepatic and extrahepatic manifestations. Key focus areas include diagnostic evaluation strategies to recognize previously undiagnosed or later-presenting disease in adults, characterization of hepatic and extrahepatic complications, and implementation of coordinated interprofessional care models. Additionally, evidence-based approaches for selecting targeted management strategies address bile acid accumulation, severe pruritus, and long-term hepatic outcomes. Interactive case-based analysis illustrates essential decision points to optimize clinical recognition, disease monitoring, and overall patient management.

• CE: 1.25 CME Hours
• Supported by: Mirum Pharmaceuticals
• Organized by: Medscape Education
• For more information and to register, visit: www.medscape.org/symposium/liver-disease-genetics